Could a 4-Week radiotherapy course be as safe as 5 weeks for prostate cancer?
NCT ID NCT07483658
First seen Mar 26, 2026 · Last updated Jun 20, 2026 · Updated 9 times
Summary
This study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. The goal is to see if the shorter schedule causes no more urinary or bowel side effects and controls the cancer just as well. About 434 men will take part, and the study will last about 12 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Québec-Université Laval
Québec, Quebec, G1G 5X1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gatineau Hospital
Gatineau, Quebec, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Général Juif
Montreal, Quebec, H3T 1E2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiotherapy (external beam radiation)
What this could lead to
If successful, this could offer men with recurrent prostate cancer a shorter, more convenient treatment option with fewer side effects, while maintaining cancer control.
What could go wrong
This is a non-inferiority trial, meaning it aims to show the shorter schedule is not worse than the standard. It is still recruiting and results will take years. There is a risk that the shorter schedule may cause more side effects or be less effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.